Collegium's abuse-deterrent oxycodone meets in Phase III

Collegium Pharmaceutical Inc. (Canton, Mass.) said Oxycodone DETERx met the primary endpoint of reducing average pain intensity from baseline to week 12 vs. placebo in a double-blind Phase III trial t...